ALTEOGEN Inc. (KOSDAQ:196170)
South Korea · Delayed Price · Currency is KRW | Market Cap | 20.33T +5.1% |
| Revenue (ttm) | 215.86B +109.9% |
| Net Income | 141.67B +127.6% |
| EPS | 2,591.24 +122.8% |
| Shares Out | 53.51M |
| PE Ratio | 146.65 |
| Forward PE | 69.96 |
| Dividend | 371.00 (0.10%) |
| Ex-Dividend Date | Dec 29, 2025 |
| Volume | 275,880 |
| Average Volume | 273,646 |
| Open | 379,500 |
| Previous Close | 380,000 |
| Day's Range | 366,000 - 379,500 |
| 52-Week Range | 315,500 - 569,000 |
| Beta | 1.07 |
| RSI | 50.12 |
| Earnings Date | May 15, 2026 |
About ALTEOGEN
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the tre... [Read more]
Financial Performance
In 2025, ALTEOGEN's revenue was 215.86 billion, an increase of 109.87% compared to the previous year's 102.85 billion. Earnings were 141.67 billion, an increase of 127.57%.
Financial StatementsNews
Alteogen Stock Up On Upto $579 Mln Deal With Biogen For Hybrozyme-Based Subcutaneous Biologics
(RTTNews) - Shares of Alteogen Inc. (196170.KQ) gained around 6 percent on Thursday's trading in South Korea after the biopharma company announced that it has entered into an exclusive license agreeme...
FDA Clears Merck's One-Minute Cancer Shot
The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co. Inc.’s (NYSE: MRK) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration i...